In vitro AL-amyloid formation by rat and human mesangial cells

Laboratory Investigation

Volumn 74, Issue 1, 1996, Pages 290-302

  Tagouri, Yahia M ^a,d,g   Sanders, Paul W ^b,c,g   Picken, Maria M ^g,h   Siegal, Gene P ^d,e,g   Kerby, Jeffrey D ^f,g   Herrera, Guillermo A ^d,g  

^a Vaughan Health Care   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Kentucky   (United States)

^g BIRMINGHAM VA MEDICAL CENTER   (United States)

^h LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID;

AMYLOIDOSIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SYNTHESIS;

AMYLOID; ANIMALS; CELLS, CULTURED; GLOMERULAR MESANGIUM; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030034953     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Alizadeh-Khiavi K and Ali-Khan Z (1988). Biochemical nature and cellular origin of amyloid enhancing factor (AEF) as determined by anti-AEF antibody. Br J Exp Pathol 69:605-619.
2. Axelrad M, Kisilevsky R, and Beswetherick S (1975). Acceleration of amyloidosis by syngenetic spleen cells from normal donors. Am J Pathol 78:277.
3. Axelrad MA, Kisilevsky R, Willmer J, Chen SJ, and Skinner M (1982). Further characterization of amyloid-enhancing factor. Lab Invest 47:139-146.
4. Benson MD, Scheinberg MA, Shirahama T, Cathcart ES, and Skinner M (1977). Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. J Clin Invest 59:412-417.
5. Calkins E and Cohen AS (1960). The diagnosis of amyloidosis. Bull Rheum Dis 10:215-218.
6. Cohen AS and Connors LH (1987). Invited review. The pathogenesis and biochemistry of amyloidosis. J Pathol 151:1-10.
7. Cohen AS and Shirahama T (1972). Animal model for human disease. Amyloidosis. Animal Model: Spontaneous and induced amyloidosis. Am J Pathol 68:441-444.
8. Cohen AS, Shirahama T, Sipe JD, and Skinner M (1983). Amyloid proteins, precursors, mediator, and enhancer (editorial). Lab Invest 48:1-3.
9. Davies M (1994). The mesangial cell: A tissue culture view. Kidney Int 45:320-327.
10. Durie BGM, Persky B, Soehnlen BJ, Grogan TM, and Salmon SE (1982). Amyloid production in human myeloma stem-cell culture with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 307:1689-1692.
11. Epstein WV, Tan M, and Wood IS (1974). Formation of "amyloid" fibrils in vitro by action of human kidney lysosomal enzymes on Bence Jones proteins. J Lab Clin Med 84:107-110.
12. Ganowiak K, Hultman P, Engström U, Gustavsson A, and Westermark P (1994). Fibrils from synthetic amyloid-related peptides enhance development of experimental AA-amyloidosis in mice. Biochem Biophys Res Commun 199: 306-312.
13. Gervais F, Hébert L, and Skamene E (1988). Amyloid-enhancing factor. Production and response in amyloidosis-susceptible and -resistant mouse strains. J Leukoc Biol 43:311-316.
14. Gise Hv, Christ H, and Bohle A (1981). Early glomerular lesions in amyloidosis: Electronmicroscopic findings. Virchows Arch [Pathol Anat] 390:259-272.
15. Glenner GG (1980). Medical Progress. Amyloid deposits and amyloidosis. The β-fibrilloses (part 1 of 2). N Engl J Med 302:1283-1292.
16. Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, and Page DL (1971a). Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science 174:712-714.
17. Glenner GG, Harbaugh J, Ohms JI, Harada M, and Cuatrecasas P (1970). An amyloid protein: The amino-terminal variable fragment of an immunoglobulin light chain. Biochem Biophys Res Commun 41:1287-1289.
18. Glenner GG, Terry W, Harada M, Isersky C, and Page D (1971b). Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analyses. Science 172:1150-1151.
19. Golde TE, Estus S, Younkin LH, Selkoe DJ, and Younkin SG (1992). Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255:728-730.
20. Gueft B and Ghidoni JJ (1963). The site of formation and ultrastructure of amyloid. Am J Pathol 43:837-854.
21. Harper PA, Robinson JM, Hoover RL, Wright TC, and Karnovsky MJ (1984). Improved methods for culturing rat glomerular cells. Kidney Int 26:875-880.
22. Herrera GA and Lott RL (1990). Colloidal gold labeling for diagnostic pathology. In: Hayat MA, editor. Colloidal gold: Principles, methods, and applications. New York: Academic Press, 321-342.
23. Hol PR, van Andel ACJ, van Ederen AM, Draaÿer J, and Gruys E (1985). Amyloid enhancing factor in hamster. Br J Exp Pathol 66:689-697.
24. Hsu SM, Raine L, and Fanger H (1981). Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580.
25. Husby G and Sletten K (1986). Amyloid proteins. In: Marrink J and van Rijswijk MH, editors. Amyloidosis. Dordrecht: Martinus Nijhoff, 23-34.
26. Kashgarian M and Sterzel RB (1992). The pathobiology of the mesangium. Kidney Int 41:524-529.
27. Kazimierczak J (1972). Ultrastructural observations on the first amyloid to be found in the spleen of casein treated mice. Acta Pathol Microbiol Scand 80:141-150.
28. Keizman I, Rimon A, Sohar E, and Gafni J (1972). Amyloid accelerating factor. Purification of a substance from human amyloidotic spleen that accelerates the formation of casein-induced murine amyloid. Acta Pathol Microbiol Scand [A] 80 (Suppl 233):172-177.
29. Kisilevsky R (1983). Amyloidosis: A familiar problem in the light of current pathogenetic developments. Lab Invest 49: 381-390.
30. Kisilevsky R, Axelrad M, Brunet S, and Richard M (1976). Effect of amyloid induction on plasma protein turnover and its implications. Am J Pathol 83:299.
31. Kisilevsky R and Boudreau L (1983). Kinetics of amyloid deposition. I. The effects of amyloid-enhancing factor and splenectomy. Lab Invest 48:53-59.
32. Knauss TC, Mené P, Ricanati SA, Kester M, Dubyak GR, Emancipator SN, and Sedor JR (1989). Immune complex activation of rat glomerular mesangial cells: Dependence on the Fc region of antibody. Am J Physiol 1989;26:F478-F485.
33. Linke RP, Zucker-Franklin D, and Franklin EC (1973). Morphologic, chemical and immunologie studies of amyloid-like fibrils formed from Bence Jones proteins by proteolysis. J Immunol 111:10-23.
34. Michael AF, Keane WF, Raij L, Vermer RC, and Mauer SM (1980). The glomerular mesangium. Kidney Int 17:141-154.
35. Micklem K, Rigney E, Cordell J, Simmons D, Stross P, Turley H, Seed B, and Mason D (1989). A human macrophage-associated antigen (CD;68) detected by six different monoclonal antibodies. Br J Haematol 73:6-11.
36. Mowry RW, Rodenbough JW, and Megginson AG (1963). Detection of amyloid in pancreatic islets of diabetics by thioflavine-T fluorescence and its comparison with traditional stains for amyloid (abstract). Am J Pathol 43:38.
37. Picken MM, Gallo GR, and Frangione B (1990). Amyloid enhancing factor and inflammatory reaction (correspondence). Lab Invest 63:586-587.
38. Puchtler H, Sweat F, and Levine M (1962). On the binding of Congo red by amyloid. J Histochem Cytochem 10:355-364.
39. Sanders PW and Booker BB (1992). Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 89:630-639.
40. Schreiner GF, Kiely J-M, Cotran RS, and Unanue ER (1981). Characterization of resident glomerular cells in the rat expressing la determinants and manifesting genetically restricted interactions with lymphocytes. J Clin Invest 68:920-931.
41. Shirahama T (1988). Amyloidogenesis and light chains. In: Minetti L, D'Amico G, and Ponticelli C, editors. The kidney in plasma cell dyscrasias. Dordrecht, Boston, and London: Kluwer Academic Publishers, The Netherlands, 57-66.
42. Shirahama T, Benson MD, Cohen AS, and Tanaka A (1973b). Fibrillar assemblage of variable segments of immunoglobulin light chains: An electron microscopic study. J Immunol 110:21-30.
43. Shirahama T and Cohen AS (1967). Fine structure of the glomerulus in human and experimental amyloidosis. Am J Pathol 51:869-911.
44. Shirahama T and Cohen AS (1973a). An analysis of the close relationship of lysosomes to early deposits of amyloid. Am J Pathol 73:97-114.
45. Shirahama T and Cohen AS (1975). Intralysosomal formation of amyloid fibrils. Am J Pathol 81:101-116.
46. Shirahama T, Lawless OJ, and Cohen AS (1969). Heterologous transfer of amyloid-human to mouse. Proc Soc Exp Biol Med 130:516-519.
47. Shirahama T, Miura K, Ju S-T, Kisilevsky R, Gruys E, and Cohen AS (1990). Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest 62:61-68.
48. Siegal GP, Wagn M-H, Rinehart CA, Kennedy JW, Goodly LJ, Miller Y, Kaufmann DG, and Singh RK (1993). Development of a novel human extracellular matrix for quantitation of the invasiveness of cells. Cancer Lett 69:123-132.
49. Skinner M, Benson MD, and Cohen AS (1975). Amyloid fibril protein related to immunoglobulin λ-chains. J Immunol 114: 1433-1435.
50. Sletten K, Westermark P, and Husby G (1986). Structural studies of the variable region of immunoglobulin light-chain-type amyloid fibril proteins. In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, and Zucker-Franklin D, editors. Amyloidosis. New York: Plenum Press, 463-475.
51. Solomon A (1985). Light chains of human immunoglobulins. In: Di Sabato G, Langone JJ, and Van Vunakis H, editors, Immunochemical techniques. Part H: Effectors and mediators of lymphoid cell functions. Methods in enzymology, vol. 116. Orlando, FL: Academic Press, 101-21.
52. Solomon A and Havemann K (1978). Bence Jones proteins and light chains of immunoglobulins-XVII. Unique susceptibility of certain κ-chains to proteolysis by human granulocyte-derived neutral proteases. Immunochemistry 15: 453-458.
53. Solomon A, Kyle RA, and Frangione B (1986). Light chain variable region subgroups of monoclonal immunoglobulins in amyloidosis AL. In: Glenner GG, Osserman EF, Benditt EP, Calkins E, Cohen AS, and Zucker-Franklin D, editors. Amyloidosis. New York: Plenum Press, 449-462.
54. Solomon A, Weiss DT, and Kattine AA (1991). Nephrotoxic potential of Bence Jones proteins. N Engl J Med 324:1845-51.
55. Stone MJ (1990). Amyloidosis: A final common pathway for protein deposition in tissues (review article). Blood 75:531-545.
56. Stone MJ and Frenkel EP (1975). The clinical spectrum of light chain myeloma: A study of 35 patients with special reference to the occurrence of amyloidosis. Am J Med 58:601-619.
57. Teilum G (1964). Pathogenesis of amyloidosis. The two-phase cellular theory of local secretion. Acta Pathol Microbiol Scand 61:21-45.
58. Varga J, Flinn MSM, Shirahama T, Rodgers OG, and Cohen AS (1986). The induction of accelerated murine amyloid with human splenic extract. Probable role of amyloid enhancing factor. Virchows Arch B [Cell Pathol] 51:177-185.
59. White GC, Jacobson RJ, Binder RA, Linke RP, and Glenner GG (1975). Immunoglobulin D myeloma and amyloidosis: Immunochemical and structural studies of Bence Jones and amyloid fibrillar proteins. Blood 46:713-722.